ClinicalTrials.gg
RecruitingNCT07868419OCEAN-2Updated Nov 13, 2026

Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets

A Phase 3 interventional study of NAL ER and Placebo in Idiopathic Pulmonary Fibrosis, sponsored by Trevi Therapeutics. Recruiting at 16 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Trevi Therapeutics · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Nov 13, 2026Newly registered12 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
201
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States — 37 open to participants now, 51 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · United States.

Planned enrollment
44th of 188
201 · median 61
Started
2026
with 15 others
Phase 3
37 of 236
6 open now
Primary completion
2027-08
later than 22 of 50 live
Registered
235th of 236
by date

Among the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, this one is the 44th largest by planned enrollment of the 188 interventional ones that give a count, is one of 16 that started in 2026, is one of 37 in phase 3, reaches primary completion later than 22 of the 50 other live ones, and was the 235th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

37 of the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, or all of them as a file.
02

Study summary

The primary purpose is to evaluate the safety and efficacy of NAL ER for the treatment of chronic cough in participants with IPF.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of IPF as determined by the Investigator based on American Thoracic Society (ATS)/European Respiratory Society (ERS)/Japanese Respiratory Society (JRS)/Latin American Thoracic Society (ALAT) clinical practice guidelines.
  • Chronic cough for ≥8 weeks prior to Screening.
  • PGI-Severity Score ≥ 2 at Screening.
  • Forced vital capacity (FVC) ≥40 percent (%) of predicted at Screening.
  • Diffusing capacity for carbon monoxide (DLCO) ≥25% of predicted during Screening or within 12 weeks prior to Screening.
  • If currently taking antifibrotic medication (nintedanib, pirfenidone, nerandomilast) should be on a stable dose for at least 6 weeks prior to the Baseline Visit.

Exclusion criteria

Exclusion Criteria:

  • Clinical diagnosis or clinical suspicion of an upper or lower respiratory tract infection in the last 8 weeks prior to the Screening visit or during Screening.
  • Hospitalization for any respiratory illness (including acute exacerbation of IPF) within 8 weeks prior to Screening.

Note: Other protocol-defined inclusion/exclusion criteria may apply.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
201 participants (estimated)

Study arms

  • Experimental
    NAL ER 54 mg

    Participants will undergo a 2-week blinded titration period followed by a fixed dose treatment period receiving NAL ER 54 milligrams (mg) twice daily (BID) for 12 weeks.

    Drug: NAL ER

  • Placebo comparator
    Placebo

    Participants will undergo a 2-week blinded titration period followed by a fixed dose treatment period receiving a matching placebo BID for 12 weeks.

    Drug: Placebo

Interventions

  • DrugNAL ER

    Oral tablets

    Also known as: Nalbuphine

  • DrugPlacebo

    Oral tablets

06

What researchers measure

Primary outcomes

  1. Relative Change from Baseline in 24-hour Cough Frequency at Week 14 for NAL ER Compared With Placebo

    Time frame: Baseline, Week 14

Secondary outcomes

  1. Absolute Change from Baseline in the Cough Severity Numerical Rating Scale (CS-NRS) at Week 14 for NAL ER Compared With Placebo

    Time frame: Baseline, Week 14

  2. Relative Change from Baseline in 24-hour Cough Frequency for NAL ER Compared With Placebo

    Time frame: Baseline, Weeks 6 and 10

  3. Absolute Change from Baseline in 24-hour Cough Frequency for NAL ER Compared With Placebo

    Time frame: Baseline, Weeks 6 and 10

  4. Proportion of Participants Achieving ≥30%, ≥50% and ≥75% Reduction from Baseline in 24-hour Cough Frequency at Week 14 for NAL ER Compared With Placebo

    Time frame: Baseline, Week 14

  5. Absolute Change from Baseline in the Evaluating Respiratory Symptoms in Idiopathic Pulmonary Fibrosis (E:RS-IPF) Cough Domain at Week 14 for NAL ER Compared With Placebo

    Time frame: Baseline, Week 14

  6. Absolute Change from Baseline in the E-RS:IPF Total Score and Domain Scores (IPF-Breathlessness, IPF-Cough, IPF-Sputum, and IPF-Chest Symptoms) at Week 14 for NAL ER Compared With Placebo

    Time frame: Baseline, Week 14

  7. Absolute Change from Baseline in the CS-NRS for NAL ER Compared With Placebo

    Time frame: Baseline up to Week 14

  8. Proportion of Participants Achieving a ≥3-point Improvement from Baseline in CS-NRS for NAL ER Compared With Placebo

    Time frame: Baseline up to Week 14

  9. Absolute Change from Baseline in the Leicester Cough Questionnaire (LCQ) Total Scores at Week 14 for NAL ER Compared With Placebo

    Time frame: Baseline, Week 14

  10. Absolute Change from Baseline in Each LCQ Domain Score (Physical, Psychological, Social) at Week 14 for NAL ER Compared With Placebo

    Time frame: Baseline, Week 14

  11. Proportion of Participants Achieving a 1.3-point Increase (Improvement) from Baseline in LCQ Total Score at Week 14 for NAL ER Compared With Placebo

    Time frame: Baseline, Week 14

  12. Change from Baseline in the European Quality of Life 5 Dimensions 5 Level (EQ-5D-5L) at Week 14 for NAL ER Compared With Placebo

    Time frame: Baseline, Week 14

  13. Relative Change from Baseline in Awake Cough Frequency at Week 14 for NAL ER Compared With Placebo

    Time frame: Baseline, Week 14

  14. Relative Change from Baseline in Sleep Cough Frequency at Week 14 for NAL ER Compared With Placebo

    Time frame: Baseline, Week 14

  15. Absolute Change from Baseline in the Patient Global Impression of Severity (PGI-S) Cough Score at Week 14 for NAL ER Compared With Placebo

    Time frame: Baseline, Week 14

  16. Absolute Change from Baseline in the Patient Global Impression of Change (PGI-C) Cough Score at Week 14 for NAL ER Compared With Placebo

    Time frame: Baseline, Week 14

  17. Proportion of Participants with Improvements by ≥1 and ≥2 Categories from Baseline on the PGI-S Cough at Week 14 for NAL ER Compared With Placebo

    Time frame: Baseline, Week 14

  18. Relative Change from Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) at Week 14 for NAL ER Compared With Placebo

    Time frame: Baseline, Week 14

  19. Safety and Tolerability as Assessed by Number of Participants with Treatment Emergent Adverse Events (TEAEs)

    Time frame: Baseline up to Week 17

07

Study locations

16 of 16 sites recruiting
  • Sec Clinical Research - Dothan
    Tuscaloosa, Alabama 35476, United States
    Recruiting
  • Starling Physicians, P.C.
    New Britain, Connecticut 06051, United States
    Recruiting
  • Premier Medical Associates, LLC
    Wilmington, Delaware 19803, United States
    Recruiting
  • D&H Doral Research Center
    Doral, Florida 33122, United States
    Recruiting
  • Blessed Health Care and Research Inc.
    Miami, Florida 33173, United States
    Recruiting
  • Coral Research Clinic Corp.
    Miami, Florida 33186, United States
    Recruiting
  • Pharma Medical Innovations, Inc.
    Miami Lakes, Florida 33016, United States
    Recruiting
  • Essential Health and Research Services
    North Miami Beach, Florida 33162, United States
    Recruiting
  • Velocity Clinical Research - Rockville
    Rockville, Maryland 20854, United States
    Recruiting
  • Vitalis Clinical Research Center LLC
    Allen Park, Michigan 48101, United States
    Recruiting
  • Veritas Clinical Research
    Warren, Missouri 48071, United States
    Recruiting
  • American Health Research - Charlotte Location
    Charlotte, North Carolina 28277, United States
    Recruiting
  • Summit Health (Summit Medical Group) - Eastside Clinic
    Bend, Oregon 97701, United States
    Recruiting
  • The Oregon Clinic - Gateway Medical Office Location - Pulmonary, Critical Care & Sleep Medicine East
    Portland, Oregon 97220, United States
    Recruiting
  • Stryde Research
    Carrollton, Texas 75010, United States
    Recruiting
  • Hillcroft Medical Clinic
    Sugar Land, Texas 77478, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Aug 2027, 11 months after the start.

Of 24 phase 3 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 60. This study's planned 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2026
First posted
Oct 9, 2026
StartActual
Sep 30, 2026
Primary completionEst.
Aug 2027
CompletionEst.
Oct 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
12 sites added
Show 12 added (12 United States)
  • Sec Clinical Research - Dothan · Tuscaloosa, United States
  • Starling Physicians, P.C. · New Britain, United States
  • D&H Doral Research Center · Doral, United States
  • Blessed Health Care and Research Inc. · Miami, United States
  • Coral Research Clinic Corp. · Miami, United States
  • Pharma Medical Innovations, Inc. · Miami Lakes, United States
  • Velocity Clinical Research - Rockville · Rockville, United States
  • Vitalis Clinical Research Center LLC · Allen Park, United States
  • Veritas Clinical Research · Warren, United States
  • Summit Health (Summit Medical Group) - Eastside Clinic · Bend, United States
  • The Oregon Clinic - Gateway Medical Office Location - Pulmonary, Critical Care & Sleep Medicine East · Portland, United States
  • Stryde Research · Carrollton, United States
Nov 13, 2026
Registered
First appeared on the registry
Oct 9, 2026
Show all 2 updates
  1. Nov 13, 2026
    12 sites added
    Show 12 added (12 United States)
    • Sec Clinical Research - Dothan · Tuscaloosa, United States
    • Starling Physicians, P.C. · New Britain, United States
    • D&H Doral Research Center · Doral, United States
    • Blessed Health Care and Research Inc. · Miami, United States
    • Coral Research Clinic Corp. · Miami, United States
    • Pharma Medical Innovations, Inc. · Miami Lakes, United States
    • Velocity Clinical Research - Rockville · Rockville, United States
    • Vitalis Clinical Research Center LLC · Allen Park, United States
    • Veritas Clinical Research · Warren, United States
    • Summit Health (Summit Medical Group) - Eastside Clinic · Bend, United States
    • The Oregon Clinic - Gateway Medical Office Location - Pulmonary, Critical Care & Sleep Medicine East · Portland, United States
    • Stryde Research · Carrollton, United States
    + 1 other change: verification date
  2. Oct 9, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07868419
Lead sponsor
Trevi Therapeutics
Responsible party
Sponsor
First posted
Oct 9, 2026
Start date
Sep 30, 2026
Primary completion
Aug 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

Paula Buckley
Contact
Paula.Buckley@trevitherapeutics.com
(203) 304-2499
Chief Development Officer
study director · Trevi Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nalbuphine

Start the discussion